Cargando…

Imaging PARP with [(18)F]rucaparib in pancreatic cancer models

PURPOSE: Rucaparib, an FDA-approved PARP inhibitor, is used as a single agent in maintenance therapy to provide promising treatment efficacy with an acceptable safety profile in various types of BRCA-mutated cancers. However, not all patients receive the same benefit from rucaparib-maintenance thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Chung Ying, Chen, Zijun, Destro, Gianluca, Veal, Mathew, Lau, Doreen, O’Neill, Edward, Dias, Gemma, Mosley, Michael, Kersemans, Veerle, Guibbal, Florian, Gouverneur, Véronique, Cornelissen, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399069/ https://www.ncbi.nlm.nih.gov/pubmed/35614267 http://dx.doi.org/10.1007/s00259-022-05835-4

Ejemplares similares

[(123)I]CC1: A PARP-Targeting, Auger Electron–Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer
por: Chan, Chung Ying, et al.
Publicado: (2023)

Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [(18)F]olaparib in mouse models of glioma
por: Chan, Chung Ying, et al.
Publicado: (2022)

[(18)F]AZD2461, an Insight on Difference in PARP Binding Profiles for DNA Damage Response PET Imaging
por: Guibbal, Florian, et al.
Publicado: (2020)

Radiofluorination of a highly potent ATM inhibitor as a potential PET imaging agent
por: Fraser, Claudia Rose, et al.
Publicado: (2022)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

Closing the gap between (19)F and (18)F chemistry
por: Ajenjo, Javier, et al.
Publicado: (2021)

Correction to: Closing the gap between (19)F and (18)F chemistry
por: Ajenjo, Javier, et al.
Publicado: (2022)

A Model System to Explore the Detection Limits of Antibody-Based Immuno-SPECT Imaging of Exclusively Intranuclear Epitopes
por: Veal, Mathew, et al.
Publicado: (2021)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023)

Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer
por: Colombo, Ilaria, et al.
Publicado: (2018)

Dual-isotope imaging allows in vivo immunohistochemistry using radiolabelled antibodies in tumours()()
por: Knight, James C., et al.
Publicado: (2019)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

Multi-patient dose synthesis of [(18)F]Flumazenil via a copper-mediated (18)F-fluorination
por: Gendron, Thibault, et al.
Publicado: (2022)

Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy
por: Kersemans, Veerle, et al.
Publicado: (2010)

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
por: Dockery, LE, et al.
Publicado: (2017)

BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair
por: Zhang, Shaolu, et al.
Publicado: (2021)

Hypoxia Imaging Using PET and SPECT: The Effects of Anesthetic and Carrier Gas on [(64)Cu]-ATSM, [(99m)Tc]-HL91 and [(18)F]-FMISO Tumor Hypoxia Accumulation
por: Kersemans, Veerle, et al.
Publicado: (2011)

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules
por: Murray, J, et al.
Publicado: (2014)

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
por: Kondrashova, Olga, et al.
Publicado: (2018)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself
por: McCrudden, Cian M., et al.
Publicado: (2015)

Imaging DNA damage response by γH2AX in vivo predicts treatment response to Lutetium-177 radioligand therapy and suggests senescence as a therapeutically desirable outcome
por: O'Neill, Edward, et al.
Publicado: (2023)

Early Detection in a Mouse Model of Pancreatic Cancer by Imaging DNA Damage Response Signaling
por: Knight, James C., et al.
Publicado: (2020)

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib
por: Liao, Mingxiang, et al.
Publicado: (2022)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Imaging of Claudin-4 in Pancreatic Ductal Adenocarcinoma Using a Radiolabelled Anti-Claudin-4 Monoclonal Antibody
por: Torres, Julia Baguña, et al.
Publicado: (2017)

Radiolabeled cCPE Peptides for SPECT Imaging of Claudin-4 Overexpression in Pancreatic Cancer
por: Torres, Julia Baguña, et al.
Publicado: (2020)

(18)F-Trifluoromethanesulfinate Enables Direct C–H (18)F-Trifluoromethylation of Native Aromatic Residues in Peptides
por: Kee, Choon Wee, et al.
Publicado: (2020)

A Carbon-Fiber Sheet Resistor for MR-, CT-, SPECT-, and PET-Compatible Temperature Maintenance in Small Animals
por: Kersemans, Veerle, et al.
Publicado: (2019)

Evaluation of phototoxicity induced by the anticancer drug rucaparib
por: Mateos-Pujante, Alejandro, et al.
Publicado: (2022)

Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain – A GEICO study
por: Yubero, Alfonso, et al.
Publicado: (2022)

Asymmetric (18)F-fluorination for applications in positron emission tomography
por: Buckingham, Faye, et al.
Publicado: (2016)

Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report
por: Simmons, Andrew D., et al.
Publicado: (2020)

(111)In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin
por: Cornelissen, Bart, et al.
Publicado: (2012)

Emerging treatment options for ovarian cancer: focus on rucaparib
por: Mariappan, Lavanya, et al.
Publicado: (2017)

Targeted treatment of advanced ovarian cancer: spotlight on rucaparib
por: Pearre, Diana C, et al.
Publicado: (2018)

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors
por: Shapiro, Geoffrey I., et al.
Publicado: (2018)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
por: Dal Molin, Graziela Z., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sct6u5r32moqus3o3ej9n04ogb